



Groups with Activities in Newborn Screening and Genetics:

- National Center for Birth Defects and Developmental Disabilities, CoCHP
- National Office of Public Health Genomics, CoCHP
- Division of Laboratory Systems, CCID
- Newborn Screening Quality Assurance Program, DLS, CCEHIP
- Newborn Screening Translational Research Initiative, DLS, CCEHIPP



New Director, National Center on Birth Defects and Developmental Disabilities

- From Washington University School of Medicine, St. Louis
- Previous: Neurologist-in-Chief at St. Louis Children's Hospital
- Recently worked with Missouri Department of Health as a Principal Investigator -- Autism and Developmental Disability Monitoring Network in Missouri



Edwin Trevathan, MD, MPH

Early Screening and Diagnosis of Duchenne Muscular Dystrophy (DMD)


- Pilot projects to test feasibility of newborn and infant screening for DMD
 - Laboratory:
 - Developed creatine kinase (CK) screening test on dried blood spots
 - Samples with elevated CK have dystrophin mutation analysis
 - Quality assurance program developed
 - Surveys developed to assess:
 - Informed consent process
 - Reasons why parents accept or decline screening
 - Families' experiences with the screening programs
 - Healthcare providers' attitudes and opinions



Feasibility and Prevalence Screen for Fragile X Syndrome (FXS)

- Automated, high-throughput screening test developed for dried blood spots
 - 100% sensitivity and specificity using 100 normal male samples and 20 full mutation male samples
 - Only identifies full mutations – no premutations
 - Will also identify sex chromosome abnormalities
- Determining the incidence of FXS using 70,000 to 100,000 blood spots leftover from NBS cards
 - De-identified cards from Georgia Newborn Screening Program
 - Prevalence of FXS and sex chromosome abnormalities

Assessing and Evaluating Historical Data Contained in the National Newborn Screening and Genetics Resource Center - Database



Vicki Stover Hertzberg, Ph.D.

Cherie James, MSPH

Emory University

Cynthia Hinton, Ph.D., MPH

Stuart Shapira, MD, Ph.D.

Centers for Disease Control and Prevention (CDC)

Lessons Learned from the Impact of Hurricane Katrina on Newborn Screening in Louisiana

Publication: Impact of hurricane Katrina on newborn screening in Louisiana,
Pediatrics, October 2007

Emad A. Yanni, MD, MSc
EIS Officer, Pediatric Genetics Team


Newborn Screening and Molecular Biology Branch, DLS, CCEHIP

- New merged branch – 47 people
 - ▶ Acting Branch Chief, Harry Hannon, Ph.D.
Seeking person (announcement) for position --
early 2008
- NSQAP/Endocrine Disorders Laboratory and
Metabolic and Hemoglobin Disorders Laboratory
- NSTRI/Immune Disorders Laboratory
- Diabetes and Molecular Risk Assessment
Laboratory
- DNA-Banking and Genetic Studies Laboratory

Co-Sponsors



Newborn Screening and Molecular Biology Branch Programs



NSQAP



**Newborn Screening
Translational
Research Initiative
[NSTRI]**

<http://www.cdc.gov/labstandards/nsqap.htm>

<http://wwwn.cdc.gov/nsqap>




Newborn Screening Quality Assurance Program

“Gaining Confidence Through an External Quality Assurance
Program for Dried-Blood Spot Testing”

- **Services provided:**


- Filter paper evaluation
- Reference materials
- Quality control materials
- Proficiency testing
- Training, consultations, network resources



- **Partners**

- Association of Public Health Laboratories
- 70 domestic screening laboratories
- Laboratories in 54 countries
- 400 plus screening laboratories worldwide

478 Laboratories in 72 Countries - in at least one program of NSQAP



 *Participant in NSQAP*



Analytes/Biomarkers included in NSQAP

- Biotinidase
- Thyroxine
- Thyroid-stimulating hormone
- 17 α -hydroxyprogesterone
- Total galactose
- Uridyltransferase (GALT)
- Citrulline
- Phenylalanine
- Leucine
- Valine
- Methionine
- Tyrosine
- Arginine
- Free carnitine (C0)
- Acetylcarnitine (C2)
- Propionylcarnitine (C3)
- **Malonylcarnitine (C3DC) ▶**
- Isobutyrylcarnitine (C4)
- Isovalerylcarnitine (C5)
- Glutarylcarnitine (C5DC)
- Hexanoylcarnitine (C6)
- Octanoylcarnitine (C8)
- Decanoylcarnitine (C10)
- **Decenoylcarnitine (C10-1) ▶**
- Myristoylcarnitine (C14)
- **Tetradecenoylcarnitine (C14-1) ▶**
- Palmitoylcarnitine (C16)
- Stearoylcarnitine (C18)
- Immunoreactive trypsinogen/
 Δ 508 mutations
- **CF DNA Mutation Panel ▶**
- Hemoglobinopathies and
 SS, SC, SD, SE mutations
- Diabetes Type 1 risk mutations
- Toxoplasmosis: IgG, IgM
- HIV type 1 antibodies
- Creatine kinase (DMD)
- Androstenedione/cortisol/11- deoxy

 **New analytes ▶**



CF Mutation Detection PT Program

- Blood is collected from adult CF patients with known mutations
- Allows testing of less common mutations and demonstrates limitations of assays.
- Collaboration between CDC, University of Wisconsin School of Medicine and Public Health, Johns Hopkins Medical Center, and Case Western University.






LSD Projects

- Objective: To facilitate newborn screening for lysosomal storage disorders (LSDs) in public health laboratories, in conjunction with Genzyme Corporation
- Current MS multiplex assay allows screening for *Pompe*, *Fabry*, *Krabbe*, *Niemann-Pick* and *Gaucher* diseases



Evaluation of Grade 903 Blood Collection Paper 1978 to 2006

(100 μ L aliquots of lysed whole blood samples - hematocrit 55%)



CLSI Standard

“Blood Collection on Filter Paper for Neonatal Screening Programs, Approved Standard”

New Edition LA4-A5 - 2007

Authors:

W. Harry Hannon, Ph.D.

Ronald J. Whitley, Ph.D.

Brad Davin

Paul Fernhoff, MD, FAAP, FACMG


Marcia Lavochnik, RN, BSN

Tuija Halonen, MSc


Julie Miller, BS

Jelili Ojodu, MPH

Brad L. Therrell, Jr., Ph.D.



10 Million Served



Thanks